GIS:FRA
Gilead Sciences
131,56 €
arrow_downward
-1,82%(-2,44) 1 d.
14. 10., 8:01:16 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre GIS…
Otvoriť
131,56 €
Vysoká
131,56 €
Nízka
131,56 €
Trh. kap.
183,41 mld.
Priem. obj.
423,00
Objem
0,00
Max. za 52 týž.
135,56 €
Min. za 52 týž.
97,79 €
Počet zamestnancov
17 tis.
Otvoriť
131,56 €
Vysoká
131,56 €
Nízka
131,56 €
Trh. kap.
183,41 mld.
Priem. obj.
423,00
Objem
0,00
Max. za 52 týž.
135,56 €
Min. za 52 týž.
97,79 €
Počet zamestnancov
17 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
ad-hoc-news.de
·
pred 2 hodinami
Gilead extends Nurix deal. Gilead Sciences stock sits 2.76 percent below its high
ad-hoc-news.de
·
pred 6 hodinami
Gilead Sciences consensus target USD 160.07: stock pre-market at EUR 131.97, minus 0.70 percent
Benzinga
·
pred 14 hodinami
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
MarketBeat
·
pred 23 hodinami
Erste Group Bank Comments on Gilead Sciences FY2027 Earnings
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Informácie o subjekte Gilead Sciences
Generálny riaditeľDaniel O'Day
Zamestnanci17 tis.
Dátum založenia22. 6. 1987
Hlavné sídloFoster City, Kalifornia, Spojené štáty americké
Odvetvie-
Webgilead.com